These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27717636)

  • 1. The effect of dalteparin on thromboelastography in pregnancy: an in vitro study.
    Chow L; Carr A; MacKenzie L; Walker A; Archer D; Lee A
    Int J Obstet Anesth; 2016 Dec; 28():22-27. PubMed ID: 27717636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro heparinization of canine whole blood with low molecular weight heparin (dalteparin) significantly and dose-dependently prolongs heparinase-modified tissue factor-activated thromboelastography parameters and prothrombinase-induced clotting time.
    Jessen LR; Wiinberg B; Jensen AL; Kjelgaard-Hansen M; Jensen KH; Pedersen LB; Kristensen AT
    Vet Clin Pathol; 2008 Dec; 37(4):363-72. PubMed ID: 19055570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboelastography (TEG®) demonstrates that tinzaparin 4500 international units has no detectable anticoagulant activity after caesarean section.
    Griffiths S; Woo C; Mansoubi V; Riccoboni A; Sabharwal A; Napier S; Columb M; Laffan M; Stocks G
    Int J Obstet Anesth; 2017 Feb; 29():50-56. PubMed ID: 27887785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of viscoelastic coagulation testing to monitor low molecular weight heparin administration to healthy horses.
    Tennent-Brown BS; Epstein KL; Whelchel DD; Giguère S
    J Vet Emerg Crit Care (San Antonio); 2013; 23(3):291-9. PubMed ID: 23656212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viscoelastic pharmacodynamics after dalteparin administration to healthy dogs.
    Brainard BM; Koenig A; Babski DM; Blong AE; Scherk JR
    Am J Vet Res; 2012 Oct; 73(10):1577-82. PubMed ID: 23013183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reference ranges for thromboelastography (TEG(®) ) and traditional coagulation tests in term parturients undergoing caesarean section under spinal anaesthesia*.
    Macafee B; Campbell JP; Ashpole K; Cox M; Matthey F; Acton L; Yentis SM
    Anaesthesia; 2012 Jul; 67(7):741-7. PubMed ID: 22486761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of thromboelastography to assess the combined role of pregnancy and obesity on coagulation: a prospective study.
    Sharma S; Uprichard J; Moretti A; Boyce H; Szydlo R; Stocks G
    Int J Obstet Anesth; 2013 Apr; 22(2):113-8. PubMed ID: 23465802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
    Abou-Nassar K; Kovacs MJ; Kahn SR; Wells P; Doucette S; Ramsay T; Clement AM; Khurana R; Mackinnon K; Blostein M; Solymoss S; Kingdom J; Sermer M; Rey E; Rodger M;
    Thromb Haemost; 2007 Jul; 98(1):163-71. PubMed ID: 17598009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.
    Ajayi AA; Pharmacols FB; Cooper J; Horn EH; Rubin PC
    Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):539-45. PubMed ID: 18040530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dalteparin dose-dependently increases ROTEM(®) thrombelastography parameters only at supratherapeutic anti-factor Xa levels: an in vitro study.
    Feuring M; Wehling M; Schultz A
    Clin Exp Pharmacol Physiol; 2011 Nov; 38(11):783-6. PubMed ID: 21883380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile.
    Gerotziafas GT; Chakroun T; Samama MM; Elalamy I
    Thromb Haemost; 2004 Dec; 92(6):1296-302. PubMed ID: 15583737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of thromboelastography to guide thromboprophylaxis after caesarean section.
    Boyce H; Hume-Smith H; Ng J; Columb MO; Stocks GM
    Int J Obstet Anesth; 2011 Jul; 20(3):213-8. PubMed ID: 21641791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An in vitro investigation of the coagulation effects of exogenous oxytocin using thromboelastography in healthy parturients.
    Butwick A; Harter S
    Anesth Analg; 2011 Aug; 113(2):323-6. PubMed ID: 21642611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy.
    Jacobsen AF; Qvigstad E; Sandset PM
    BJOG; 2003 Feb; 110(2):139-44. PubMed ID: 12618157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation.
    Schambeck CM; Eberl E; Geisen U; Grossmann R; Keller F
    Thromb Haemost; 2001 May; 85(5):782-6. PubMed ID: 11372668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
    Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
    J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro evidence of gender-related heparin resistance.
    Monte S; Lyons G
    Int J Obstet Anesth; 2004 Apr; 13(2):91-4. PubMed ID: 15321411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J; Johnston N; Siegbahn A
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
    Frank RD; Brandenburg VM; Lanzmich R; Floege J
    Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.